Iris Dorbian

Arsenal has set a $150 million target for its third fund, according to an SEC filing. Arsenal is a growth equity firm focused on "the intersection of the government, large corporations and emerging technology companies."

DialogTech has acquired Swydo, a provider of digital marketing dashboards, reports and visualizations. No financial terms were disclosed. According to Crunchbase, DialogTech's backers include Second Century Ventures and Apex Venture Partners.

CMAB Biopharma Inc, a Chinese provider of process development and manufacturing services for biologic products, has raised $38 million in Series A financing. C-Bridge Capital and BioBAY led the round with participation from I-Bridge Capital and Qianhai FoF.

Boston-based Centrexion Therapeutics Corporation, a developer of treatments for chronic pain, has closed $67 million in Series D financing. New Enterprise Associates led the round with participation from other investors that included Quan Capital, ArrowMark Partners, certain investment funds advised by Clough Capital Partners L.P., InterWest Partners, 6 Dimensions Capital and Efung Capital. In conjunction with the funding, Centrexion has appointed Dr. Sara Nayeem, a partner at NEA, and Dr. Stella Xu, a managing director at Quan Capital, to its board of directors. Leerink Partners LLC was financial adviser on the transaction.

Austin-based TrendKite, a provider of PR analytics for agencies and corporate brands, has raised an additional amount of funding, bringing the company's total tally to over $46 million, according to a company announcement posted on its site. Although the exact amount of capital raised in the latest round was not specified in the blog post, TechCrunch reports the amount to be $11 million. Harmony Partners led the round.

Redwood City, California-based Armo BioSciences Inc, a late-stage immuno-oncology company, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. The company is planning on trading its stock on the NASDAQ under the ticker symbol "ARMO." Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp are the lead underwriters. Armo's backers include Qiming Venture Partners, Decheng Capital, Sequoia Capital, Quan Capital, RTW Investments, Kleiner Perkins Caufield and Byers, OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments and GV.

SuperMeat, an Israeli biotech and food tech startup, has raised $3 million in seed funding. New Crop Capital and Stray Dog Capital led the round.

Boston and San Francisco-based PEAR Therapeutics, a provider of prescription digital therapeutics, has secured $50 million in Series B financing. Temasek led the round with participation from other investors that included 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, EDBI and the Bridge Builder’s Collaborative.

Cambridge, Massachusetts-based LogicBio Therapeutics, a genome editing company, has expanded its leadership team with four new appointments: Matthias Jaffe is now chief financial officer; Tom Wilton has become chief business officer; Nelson Chau is now vice president of biology; and Kelly Blackburn is clinical and regulatory strategist. LogicBio's backers include Arix Bioscience, OrbiMed, Edmond De Rothschild Investment Partners, Pontifax, SBI and OrbiMed Israel Partners.

Magma Partners has raised $5 million for its second fund, according to an SEC filing. The target is $15 million. Magma Partners is a seed-stage venture firm that helps Latin American entrepreneurs launch and scale in the U.S. market.